Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD, discuss frontline, second-line, and antibody-drug conjugate therapies for the treatment of HR-positive, HER2-negative metastatic breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Interpret recent clinical trial data evaluating new therapies and novel combinations for the treatment of HR+/HER2- metastatic breast cancer (MBC)
• Develop individualized treatment plans that utilize targeted therapies for patients with endocrine-sensitive HR+/HER2- MBC
• Incorporate the best available evidence to select and sequence antibody-drug conjugates for the treatment of endocrine-resistant HR+/HER2-low MBC
• Implement strategies to manage treatment-related adverse events and support adherence through patient education and shared decision-making

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca; BioNTech; Genentech, Inc; and Stemline Therapeutics, Inc.

Chair:

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, TN

Disclosures: Consultant (all payments to institution): Accutar Biotechnology, Arvinas, AstraZeneca, BeiGene, Circle Pharma, Daiichi Sankyo, Entos, Gilead Sciences, Halda Therapeutics, Incyclix Bio, IQVIA, Janssen, Jazz Pharmaceuticals, Jefferies LLC, Johnson and Johnson, Lilly, Medical Pharma Services, Mersana, Novartis, Pfizer, Pyxis Oncology, Roche/Genentech, Samsung Bioepis, Shorla Pharma, Stemline Therapeutics, Tempus Labs, Zentalis Pharmaceuticals; Research Funding (all payments to institution): AbbVie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals , Boehringer Ingelheim, Bristol-Myers Squibb, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics , Cullinan, Curis, CytomX, Daiichi Sankyo, Dana Farber Cancer Inst, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Eisai, Ellipses Pharma, Elucida Oncology, EMD Serono, Fochon Pharmaceuticals, FujiFilm, G1 Therapeutics, Gilead Sciences, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals , Inspirna, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals , Leap Therapeutics, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema, OncoMed, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals , Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, StemCentRx, Stemline Therapeutics, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Zenith Epigenetics, Zymeworks

Faculty:

Giuseppe Curigliano, MD, PhD

Professor of Medical Oncology
University of Milan
Director, Early Drug Development Division
European Institute of Oncology
Milan, Italy

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Biontech, Daichii Sankyo, Exact Sciences, Lilly, Menarini, Merck, Novartis, Pfizer, Roche

VK Gadi, MD, PhD

Professor of Clinical Medicine
Division of Hematology and Oncology
University of Illinois Cancer Center
Director, Medical Oncology
University of Illinois College of Medicine
Chicago, IL

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Genentech, Gilead, Hologic, Novartis, Pfizer, Stemline; Grant/Research Funding: Agendia, AstraZeneca, Illimuna, Gilead, Glaxo-Smith-Kline, Novartis; Ownership Interests: Tempus

Jason Aboudi Mouabbi, MD

Assistant Professor, Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Agendia, Aptitude Health, AstraZeneca, BostonGene, Community Health Media, GE HealthCare, PreludeDX, Stemline; Grant/Research Funding: Bristol Myers Squibb, Summit Therapeutics

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including expert answers to audience questions, go to https://www.gotoper.com/sabcs25armamentarium-enduring.

Release Date

January 20, 2026

Expiration Date

January 20, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.